Key targets and new therapeutic approaches for Neuroblastoma: From the bench to the bedside.

Ce.S.I-MET, Research Institute, University of Chieti-Pescara
Via Dei polacchi 11,
66100 Chieti, Italy.

Thursday, 15 February

-Arrival and registration: 15:00

- 15:30 Conference opening and introduction to the CESI-Met institute (Vincenzo De Laurenzi)
- 15:40 Introduction to neuroblastoma (Arturo Sala)

Immunotherapy I (Session chairs: Arturo Sala; V De Laurenzi)

- 15:50 Franco Locatelli, Ospedale Bambin Gesu’. Development of a third-generation GD2-specific CAR construct to treat children with neuroblastoma
- 16:30 Loredana Cifaldi, Ospedale Bambin Gesu’. Boosting Natural Killer cell-based immunotherapy of high-risk neuroblastoma: new molecular strategies
- 16:55 Doriana Fruci, Ospedale Bambin Gesu’. Immune microenvironment in neuroblastoma: clinical and therapeutic relevance
- 17:20 Keynote speaker: Waseem Qasim, UCL Institute of Child Health. Gene edited T cells for leukaemia

- 18:00 Welcome Cocktail.
- 19:00 Bus to Hotel

Friday, 16th February

-9:30 Sara Costa, Associazione Italiana per la Lotta al Neuroblastoma

MYCN (Session Chair: Giovanni Perini, Giuseppe Giannini)

-10:00 Giovanni Perini, Universita’ di Bologna. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma
-10:25 Alexia Tsakaneli, Brunel University London. MYCN regulates exosome protein cargo in neuroblastoma
-10:50 Victor Corasolla Carregari, Universita’ Tor Vergata. MYCN modulation of membrane proteins expression in neuroblastoma cell lines

-11:15 Coffee break
-11:45 Valeria Colicchia, Universita’ di Roma La Sapienza. Targeting the replication stress response by combined PARP and CHK1 inhibition: a new strategy to treat MYCN amplified neuroblastoma.

-12:05 Marialaura Petroni, Universita’ di Roma La Sapienza. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN amplified neuroblastoma

-12:30 Lunch

Small molecules and new targets (Session Chair: Mario Capasso, Michele Sallese)

-13:30 Paolo Ciufici, Universita’ di Chieti-Pescara. A Molecularly driven pharmacological approach for neuroblastoma: targeting TERT and CKS1b

-13:55 Sanja Aveic, Pediatric Research Institute - Città’ della Speranza, Padova. Autophagy block as an attempting approach to improve the cytotoxic effects of receptor tyrosine kinase inhibitors

-14:20 Flora Cimmino, Universita’ di Napoli. FGFR1 N546K is oncogenic driver mutation in neuroblastoma

-14:45 Francesca Broso, Universita’ di Trento. A screening for natural products identifies a flavonol as a synergistic compound with 13-cis retinoic acid in neuroblastoma

-15:10 Giuseppe Raschella’, ENEA. ZNF281 controls neuroblastoma differentiation in a TA-p73/miR34a/MYCN regulatory axis

-15:35 Simona Cocchi, Universita’ di Trento. Targeting the Lin28/let-7 axis by small molecules in neuroblastoma

-16:00 Coffee break

Immunotherapy II (Session Chair: Vito Pistoia, Franco Locatelli)

-16:20 Gianluca Sala, Universita’ di Chieti-Pescara; Mediapharma. Antibody Drug Conjugates for cancer therapy

-16:45 Ignazio Caruana, Ospedale Bambin Gesu’. Generation of T lymphocytes genetically modified to express third generation GD2-specific chimeric antigen receptor (CAR) with CD28/4.1BB costimulation to improve anti-tumour efficacy of adoptive T cell therapy for patients with neuroblastoma

-17:10 Valeria Corrias, Ospedale Gaslini. Bone marrow disease in neuroblastoma

-17:35 General Discussion and concluding remarks

-18:15 Bus to hotel

-20:30 Gala Dinner, Restaurant “Le Terrazze”, Pescara.